Latest news with #MerckAndCo
Yahoo
5 days ago
- Business
- Yahoo
Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating
Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Invest in for High Returns. On July 30, Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) while reducing the price target from $99 to $94. The analyst noted that despite recent complexities in the company's financial update released on July 29, the bottom line surpassed expectations. Moreover, the Gardasil vaccine franchise in the United States and China has been a concern, however, the company's new product Winrevair is showing strong growth potential. Management is optimistic about expanding its label and anticipates supportive data from the HYPERION trial later this year, which boosts confidence in future growth. A close-up of a person's hand holding a bottle of pharmaceuticals. Haider also highlighted the company's $3 billion optimization plan as another positive. Through this initiative the company aims to shift resources from slower-growth areas to new product launches and research and development. The analyst believes that while this might increase costs temporarily however, it supports long term expansion. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and sells prescription medicines, vaccines, and animal health products. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
21-07-2025
- Business
- Yahoo
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production
We recently published Merck & Co., Inc. stands seventh on our list and recently boosted Keytruda's production. Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical leader headquartered in Rahway, New Jersey, is renowned for its innovation in oncology, vaccines, and specialty medicines. In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 (CPS ≥1). This marks the first approval of an anti-PD-1 therapy in the perioperative setting, allowing use both before and after surgery, combined with radiotherapy and as a standalone treatment. This milestone supports the company's strategy to move immunotherapy into earlier stages of cancer care. Merck & Co., Inc. (NYSE:MRK) is also expanding its oncology pipeline, sharing promising updates on KRAS G12C inhibitor MK-1084, zilovertamab vedotin, and sacituzumab tirumotecan, as well as new analyses of KEYTRUDA across over 25 cancer types. A pharmacist technician sorting pills in a drug pharmacy. To meet growing demand and support biologics innovation, Merck & Co., Inc. (NYSE:MRK) began construction of a $1 billion Biologics Center of Excellence in Wilmington, Delaware, in April 2025. The 470,000-square-foot facility will focus on next-gen biologics and serve as the U.S. manufacturing hub for KEYTRUDA, bolstering supply chain resilience and production capacity. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-07-2025
- Business
- Yahoo
Merck's (MRK) Dividend History: A Track Record of Consistency
Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A close-up of a person's hand holding a bottle of pharmaceuticals. The company has a strong lineup of products in development and brings in solid revenue and earnings. It remains focused on innovation, with recent regulatory approvals including Winrevair, a treatment for pulmonary arterial hypertension, and Enflonsia, a vaccine targeting respiratory syncytial virus (RSV). Merck & Co., Inc. (NYSE:MRK) reported solid earnings in the first quarter of 2025. The company's revenue came in at $15.5 billion, down nearly 2% from the same period last year, but beat analysts' estimates by over $198 million. Sales of KEYTRUDA rose by 4% to reach $7.2 billion, or 6% growth when adjusted for foreign exchange effects. WINREVAIR brought in $280 million in revenue. Meanwhile, Merck's Animal Health segment saw a 5% increase in sales to $1.6 billion, and a 10% rise when excluding the impact of currency fluctuations. In addition to these quarterly earnings, Merck & Co., Inc. (NYSE:MRK) has shown its resilience as a dividend stock. The company has been rewarding shareholders with growing dividends for the past 14 years. Currently, it offers a quarterly dividend of $0.81 per share and has a dividend yield of 4.05%, as of July 17. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
19-07-2025
- Business
- Yahoo
Morgan Stanley Lowered the Firm's PT on Merck & Co (MRK), Kept a Hold Rating
Merck & Co., Inc. (NYSE:MRK) is one of the . On July 10, Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Hold rating on the stock. This small reduction reflects a cautious outlook amid broader challenges facing large pharma companies this year. Flynn highlighted that the company, like its peers, has underperformed due to the challenging macroeconomic environment. He pointed out that ongoing policy uncertainties, including drug pricing reforms, tariffs, transfer pricing issues, and changes in FDA staffing, are adding complexity to the business climate. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) faced a 2% decrease in total worldwide sales during the fiscal first quarter of 2025. The company expects full-year sales to be between $64.1 billion and $65.6 billion. Merck & Co., Inc. (NYSE:MRK) is a healthcare company that develops and sells prescription medicines, vaccines, and animal health products. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
